Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
about
Stem Cell Modeling of Core Binding Factor Acute Myeloid LeukemiaPrognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-AnalysisCore Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic OpportunitiesAcute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposideHistone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid LeukemiaComplex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in KoreaComprehensive mutational profiling of core binding factor acute myeloid leukemia.Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemiaNrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute leukemia.Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemiasMinimal residual disease in acute myeloid leukaemiaMolecular signatures in acute myeloid leukemia.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysisAdvances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaGene mutations and molecularly targeted therapies in acute myeloid leukemia.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the makingBortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report.Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemiaImpact of residual normal metaphases in core binding factor acute myeloid leukemiaPrognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Current therapeutic strategies for acute myeloid leukaemia.Geographic heterogeneity of the AML1-ETO fusion gene in Iranian patients with acute myeloid leukemia.Treatment of acute myeloid leukemia in older patients.Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.Prognostic markers in AML: focus on CBFL
P2860
Q26765858-949DEC7F-47BB-493B-B499-7CC2A83D43ACQ26771740-716D325C-C1C2-4018-8573-11667C5B5F17Q26863756-50B72EEB-9A66-4EC3-9250-9F9989BE7312Q27851694-29361A1A-528E-492E-86DF-7C14EBC6C476Q28389548-936599D2-4B2C-49E6-83D7-50774734A5D5Q29394054-2FB19246-442A-479E-BCDA-3BB7E5620511Q33421005-5F9C6A8D-56CA-48A3-9163-9FC2478F3685Q33555627-6667979E-FBDB-4DEB-8D2A-240F9B316E09Q33565514-B4652647-8D33-4DC3-8126-BFCFCCA3BADDQ33758306-7A38A3B0-E90A-4F00-A79E-2A01A0D01755Q33774508-AFBC85BE-0F5D-4247-B977-461E92D7D4B1Q33917204-EA7AA39C-3717-48E3-AD48-33099E69AD8CQ34029392-E83A381A-5888-47CA-8C72-DB1BF0DD9641Q34106837-D02406DF-3891-46F8-86AA-B5F39746FD59Q34169601-E9D6C1E0-1D05-4D28-A22B-7FC6FB86A922Q34179265-5D3E2B19-8A1C-47BC-9E9C-56B63FF1D447Q34403639-7F252225-12D8-4BB8-9767-6EA904AAB253Q34428556-CF1CD379-749B-4946-A6A2-084DEB6B7838Q34598109-CEFA1E5F-B382-4621-81D8-EA122020D3CFQ34647741-8B19E2CF-27C5-4074-B386-7B2D3CDFB1FFQ34663691-99FC3989-F881-4EDF-B5CF-B267FC8AD887Q35096486-7DDB9314-7547-4EB7-A093-496DB2C4638AQ35331086-17FF5F80-7889-4877-ADB0-C0DFD1E6D0D3Q35361598-3F1B274A-569D-43CC-96EB-A843D2365FF4Q35606252-F402BC63-850F-46D0-A4EE-4EF7A64E8B07Q35642451-90300C7A-6AE9-43A3-BC1F-27FB022838C3Q35786902-720EA390-628E-4F16-9B03-7CF81909D784Q35849281-69C22507-9515-49DF-AB07-EA8489F81AD7Q35877004-58BDB646-E678-4332-ACF4-F45591C09EABQ35958324-28AE7F96-D27F-4F63-BD15-B4CBAB56F0F4Q36373507-A31BB352-47FF-4EF8-89AC-68FC49497B34Q36375411-4409E008-F309-4E11-A639-C1BE2821FBF8Q36457184-F7772E8B-21A2-4E38-BAF9-FE93BFF80337Q36529502-F6A928CA-6E4F-49BE-AA5F-E5C0C845E346Q36539598-15FF3FBE-7B92-42FB-9421-E2143D07CAA5Q36589551-83DA1129-9548-4781-92EE-EBA1B910F5F6Q36752023-F61250F3-F033-446C-8CCA-E472E235D989Q36753274-10CEC00D-0C86-4EDD-9421-8F3E47554B44Q36808186-251A7483-CA5E-43DF-9137-2D53FA8C499FQ36852251-9F8F0BAD-EE31-4806-A3B0-5C3A5DAB860D
P2860
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Prognostic factors and outcome ...... eloid leukemia patients with t
@nl
Prognostic factors and outcome ...... er and Leukemia Group B study.
@en
type
label
Prognostic factors and outcome ...... eloid leukemia patients with t
@nl
Prognostic factors and outcome ...... er and Leukemia Group B study.
@en
prefLabel
Prognostic factors and outcome ...... eloid leukemia patients with t
@nl
Prognostic factors and outcome ...... er and Leukemia Group B study.
@en
P2093
P50
P356
P1476
Prognostic factors and outcome ...... er and Leukemia Group B study.
@en
P2093
Amy S Ruppert
Andrew J Carroll
Bayard L Powell
Charles A Schiffer
Colin G Edwards
James W Vardiman
Jonathan E Kolitz
Joseph O Moore
Lisa J Sterling
Mark J Pettenati
P304
P356
10.1200/JCO.2005.15.610
P407
P577
2005-08-01T00:00:00Z